(Q45248999)

English

Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Alzheimer's disease

0 references

0 references

Sally A Frautschy

7

object named as

Sally A Frautschy

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Takashi Morihara

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Bruce Teter

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Fusheng Yang

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Giselle P Lim

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sally Boudinot

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

F Douglas Boudinot

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Greg M Cole

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1111-1120

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300668

0 references

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Clinical pharmacokinetics of ibuprofen. The first 30 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Distortion of allelic expression of apolipoprotein E in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Transforming growth factor-beta 1 induces neuronal and astrocyte genes: tubulin alpha 1, glial fibrillary acidic protein and clusterin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Glial fibrillary acidic protein: regulation by hormones, cytokines, and growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Double placebo design in a prevention trial for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Inflammatory processes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Selective inhibition of Abeta42 production by NSAID R-enantiomers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Interleukin-1 and the immunogenetics of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Interleukin-1, neuroinflammation, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Distribution of plasma alpha 1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Genetic variation in alpha(1)-antichymotrypsin and its association with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Up-regulated production and activation of the complement system in Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

21 January 2018

Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of cytokine secretion and amyloid precursor protein processing by proinflammatory amyloid beta (A beta).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300668

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300668

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45248999&oldid=2071315316"